Tirzepatide
Source / Derivation:
​​
Tirzepatide is a synthetic dual incretin peptide designed to activate both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It is modeled after native incretin hormones involved in metabolic regulation, appetite control, and glucose homeostasis.
.png)
Tirzepatide
Mechanism of Action:
​
Tirzepatide enhances insulin secretion, improves insulin sensitivity, slows gastric emptying, and reduces glucagon release through coordinated GIP/GLP-1 receptor activation. The dual-agonist profile produces complementary effects on energy balance, appetite regulation, and metabolic efficiency.
​
Clinical Relevance & Potential Outcomes:
​
Clinical research demonstrates that tirzepatide may support significant improvements in glycemic control, weight reduction, and metabolic markers, including measures of adiposity and insulin resistance. It has also been explored for its ability to influence satiety, caloric intake, and cardiometabolic risk factors.
​
Intended Clinical Application:
​​
Tirzepatide may be relevant for individuals requiring metabolic support, body-composition improvement, or enhanced glycemic regulation, particularly in contexts of insulin resistance, impaired glucose control, or weight-management interventions.
Formulation & Quality Specifications:
​
-
Delivered as a liquid prefilled pen
-
Purity: >98% (HPLC-validated)
-
Storage: 2–8 °C (refrigerated)
-
Documentation: Full CoA and MSDS available
Concentration:​
10 mg/ml, total 3 ml, total 30 mg
Frequency:
Once per week
Dosage (pen clicks):
Weeks 1-4: Start with a dose of 2.5 per week.
Weeks 5-8: Increase the dose to 5 per week.
Weeks 9-52: Raise to a maximum dose of
7.5 per week, maintaining this level up to 1 year.
Duration:
1 month​
Notes:
No specific break required unless side effects are observed.